These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35403975)

  • 1. Acute phase of Kawasaki disease: a review of national guideline recommendations.
    Scherler L; Haas NA; Tengler A; Pattathu J; Mandilaras G; Jakob A
    Eur J Pediatr; 2022 Jul; 181(7):2563-2573. PubMed ID: 35403975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM; Shulman ST
    J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
    Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
    Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin for the treatment of Kawasaki disease.
    Broderick C; Kobayashi S; Suto M; Ito S; Kobayashi T
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014884. PubMed ID: 36695415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
    Wu Y; Liu FF; Xu Y; Wang JJ; Samadli S; Wu YF; Liu HH; Chen WX; Luo HH; Zhang DD; Wei W; Hu P
    Clin Exp Med; 2019 May; 19(2):173-181. PubMed ID: 30617865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
    PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S; Liu FF; Mammadov G; Wang JJ; Liu HH; Wu YF; Luo HH; Wu Y; Chen WX; Zhang DD; Wei W; Hu P
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):53. PubMed ID: 31366406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey.
    Cattalini M; Della Paolera S; Zunica F; Bracaglia C; Giangreco M; Verdoni L; Meini A; Sottile R; Caorsi R; Zuccotti G; Fabi M; Montin D; Meneghel A; Consolaro A; Dellepiane RM; Maggio MC; La Torre F; Marchesi A; Simonini G; Villani A; Cimaz R; Ravelli A; Taddio A;
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):29. PubMed ID: 33726806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease.
    Tang B; Lo HH; Lei C; U KI; Hsiao WW; Guo X; Bai J; Wong VK; Law BY
    Phytomedicine; 2020 Apr; 70():153208. PubMed ID: 32283413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
    EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease.
    Gorelik M; Chung SA; Ardalan K; Binstadt BA; Friedman K; Hayward K; Imundo LF; Lapidus SK; Kim S; Son MB; Sule S; Tremoulet AH; Van Mater H; Yildirim-Toruner C; Langford CA; Maz M; Abril A; Guyatt G; Archer AM; Conn DL; Full KA; Grayson PC; Ibarra MF; Merkel PA; Rhee RL; Seo P; Stone JH; Sundel RP; Vitobaldi OI; Warner A; Byram K; Dua AB; Husainat N; James KE; Kalot M; Lin YC; Springer JM; Turgunbaev M; Villa-Forte A; Turner AS; Mustafa RA
    Arthritis Care Res (Hoboken); 2022 Apr; 74(4):538-548. PubMed ID: 35257507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease.
    Gorelik M; Chung SA; Ardalan K; Binstadt BA; Friedman K; Hayward K; Imundo LF; Lapidus SK; Kim S; Son MB; Sule S; Tremoulet AH; Van Mater H; Yildirim-Toruner C; Langford CA; Maz M; Abril A; Guyatt G; Archer AM; Conn DL; Full KA; Grayson PC; Ibarra MF; Merkel PA; Rhee RL; Seo P; Stone JH; Sundel RP; Vitobaldi OI; Warner A; Byram K; Dua AB; Husainat N; James KE; Kalot M; Lin YC; Springer JM; Turgunbaev M; Villa-Forte A; Turner AS; Mustafa RA
    Arthritis Rheumatol; 2022 Apr; 74(4):586-596. PubMed ID: 35257501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
    Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guideline-Concordant Treatment of Kawasaki Disease With Immunoglobulin and Aspirin and the Incidence of Coronary Artery Aneurysm.
    Michihata N; Matsui H; Fushimi K; Yasunaga H
    Clin Pediatr (Phila); 2015 Oct; 54(11):1076-80. PubMed ID: 25573948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Usefulness of Platelet-derived Microparticle as Biomarker of Antiplatelet Therapy in Kawasaki Disease.
    Kim HJ; Choi EH; Lim YJ; Kil HR
    J Korean Med Sci; 2017 Jul; 32(7):1147-1153. PubMed ID: 28581272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kawasaki Disease - A Review of Treatment and Outcomes in an Irish Paediatric Cohort 2010-14.
    Flinn AM; Gavin PJ; McMahon CJ; Oslizok P; Butler KM
    Ir Med J; 2018 Feb; 111(2):691. PubMed ID: 29952440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte hydrogen sulfide production predicts intravenous immunoglobulin resistance in children with Kawasaki disease: A preliminary, single-center, case-control study.
    Lin J; Zhao H; Jiao F; Ma L; Ma L
    Medicine (Baltimore); 2018 Nov; 97(47):e13069. PubMed ID: 30461609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The changes of coagulation profiles in Kawasaki disease and its associations with clinical classification, intravenous immunoglobulin responsiveness and coronary artery involvement.
    Li DT; Yang Q; Xia CY; Zhang YF; Cai Y; Wu SQ; Jiang Q; Hu P
    Clin Exp Med; 2024 Aug; 24(1):177. PubMed ID: 39105936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of acute and refractory Kawasaki disease.
    Tacke CE; Burgner D; Kuipers IM; Kuijpers TW
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1203-15. PubMed ID: 23199405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
    Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.